Comparison · NCT04550936-9d2be1cf
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 6. Trial comparisons, record NCT04550936-9d2be1cf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04550936-9d2be1cf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.129 | 0.0898 | 0.183 | wilson | |
| Risk in group 2 | 0.118 | 0.0329 | 0.343 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0117 | -0.217 | 0.112 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.285 | 4.24 | log | |
| Odds ratio, group 1 over group 2 | 1.11 | 0.241 | 5.16 | log | |
| Number needed to treat, for one more participant with the outcome on Invasive Aspergillosis than on Mucormycosis | 85.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Invasive Aspergillosis | Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group. | 26 | 201 | OG000 |
| Group 2 | Mucormycosis | Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group. | 2 | 17 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Serious Adverse Event at Week 6
- Description
Serious adverse event = any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect. Number of participants with any serious adverse event based on the medical records at Week 6 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.
- Time frame
- Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
- Population
- Analysis population included all eligible participants whose data was retrieved and analyzed in this study.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
- NCT number
- NCT04550936
- Phases
- Conditions
- Invasive Aspergillosis, Mucormycosis
- Interventions
- Isavuconazole
- Lead sponsor
- Pfizer
- Results first posted
- 2025-12-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04550936?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04550936-9d2be1cf